Stratifying indeterminate cytology thyroid nodules by combining Thyroid Imaging Reporting and Data Systems (TI-RADS) and The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC)

Objective@#To determine the risk of malignancy of Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) indeterminate Thyroid Nodules (Bethesda III, IV and V) by combining cytologic (TSBRTC) and Thyroid Imaging Reporting and Data Systems (TI-RADS) ultrasonographic features based on final histopathology.@*Methods@#Design: Retrospective review of records. Setting: Tertiary Private Training Hospital. Participants: 551 records. @*Results@#Among 81 eligible participants, 59 out of 84 nodules (70.24%) wer malignant on histopathology. The malignancy risk of Bethesda classification was 60.87% (28 out of 46) for Bethesda III, 57.14% (8 out of 14) for Bethesda IV and 95.83% for Bethesda V. The malignancy risk for TI-RADS categories was 0 % (0/1) for TI-RADS 2, 50% (10 out of 20) for TI-RADS 3, 71.05 % for TI-RADS 4 and 91.67 % for TI-RADS 5. The highest risk of malignancy (100%) was associated with [Bethesda IV/TI-RADS 1, 2, and 3], [Bethesda V/TI-RADS 1, 2 and 3 [Bethesda IV and V/TI-RADS 1, 2 and 3] and [Bethesda IV/TI-RADS 5]. The lowest risk of malignancy (33.33%) was associated with [Bethesda III/TI-RADS1, 2 and 3]. A high Bethesda classification (Bethesda V) was almost 5x more likely to have a malignant anatomorphology compared with Bethesda III (p = .05) while a TI-RADS 4 or 5 category was almost 5x more likely to have a malignant anatomorphology compared to TI-RADS 1, 2 or 3 (p = .026).@*Conclusion@#This study showed that TI-RADS scoring is a sensitive diagnostic classification in recognizing patients with thyroid cancer and combining Bethesda classification and TI-RADS scoring increases the sensitivity in the diagnosis of malignant thyroid nodules. A higher likelihood of malignancy is associated with higher Bethesda classification and TI-RADS scoring.

Combination of ultrasound guided fine needle aspiration biopsy and molecular analy-sis for the differential diagnosis of thyroid nodules / 中国肿瘤临床

Recently,the incidence of papillary thyroid carcinoma(PTC)has been increasing yearly.Ultrasonography is considered the first tool in the screening and diagnosis of thyroid nodules.Ultrasound-guided fine needle aspiration(US-FNA)biopsy is an effective, minimally invasive intervention for the differential diagnosis of thyroid nodules before operation.The diagnosis of US-FNA is classified by the Bethesda diagnostic system. Although fine needle aspiration cytology has high sensitivity and specificity, unclear diagnoses, such as atypical follicular lesions,are still existed.US-FNA combined with genetic mutation analysis(BRAF,RAS,and RET/PTC rearrange-ment)for such atypical lesions(BethesdaⅢ-Ⅴ),as well as microRNA analysis,can significantly improve the diagnostic accuracy of in-definite nodules.This process facilitates standardized clinical management of benign and malignant thyroid nodules.